Luminary Group’s Post

🤝Our CEO, Bruno BARIOHAY, Ph.D, and our CSO, Julien ROUX, Ph.D., co-founded Biomeostasis back in 2010! 🥼Thanks to a passionate and dedicated expert scientific team, they have successfully made Biomeostasis one of the most trusted and recognized Preclinical #CRO for its science-driven efficacy and costumer-oriented approach! ✨ Biomeostasis is so proud to have been designing and managing more than 325 in vivo studies world-wide over the past 13 years! 🧨 Stay tuned to follow our adventures! 👉 Biomeostasis #PreclinicalResearch #Sciences #CROJourney

A big day at Juvena Therapeutics, as their lead candidate, JUV-161, has received positive FDA feedback and Orphan Disease Designation (ODD) for the treatment of Myotonic Dystrophy Type 1 (DM1). This is a major win for the broader ecosystem as an example of how founder-led biotech can truly change how we think of addressing unmet medical needs. As an early investor, I take immense pride in the team's dedicated efforts over the course of five and a half years, involving hard work and determination, to establish a world-class, fully integrated platform for the discovery and development of biologics. Their unique approach to repairing and restoring muscle health with a biologic that enhances muscle regeneration, metabolism, and function, countering the effects of aging and degenerative disease. Congrats Hanadie Yousef, Jeremy O'Connell, Neil Berkley, Mo Tabrizi, all the scientists, biologists, engineers, rest of the team, other investors, and the many partners who have believed in this group. Big things ahead!!! 🚀 Link to the announcement: https://lnkd.in/gvRTC2NS #biotech #venturecapital #founderled #healthcare #MyotonicDystrophy #RareDisease #unmetmedicalneed #healthspan #sarcopenia

@Veristat's comprehensive planning is the key to success for a biotech company's first Phase I trial. From lab to clinic, Veristat's roadmap to success is a testament to the importance of careful planning in clinical development. Take a closer look at this success story and learn the key takeaway: Planning is the foundation of success. Download the case study today > https://lnkd.in/gnz5K_7f Interested in learning more? Reach out! #CancerAntibody #Veristat

Gene&Cell Therapy >> J&J and Legend say Carvykti improves survival in earlier-line multiple myeloma: In a late-stage study, Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvykti improved survival in multiple myeloma patients who had received one to three prior lines of therapy compared to treatments typically used for the disease, the companies said Tuesday. Carvykti’s expanded approval in April was based on the same study that showed the treatment staved off disease progression in multiple myeloma patients who received at least one prior line of therapy. But survival benefit is a gold standard result for physicians, and the new data could help solidify Carvykti’s place in earlier lines of treatment. But J&J and Legend did not disclose the overall survival numbers in their respective press releases, stating that more details would be shared at a future medical meeting. The 419-patient CARTITUDE-4 study pitted Carvykti against a cocktail of either Pomalyst, bortezomib, dexamethasone or Pomalyst, dexamethasone and J&J’s Darzalex. Previously, patients were only eligible for Carvykti after four previous lines of therapy — meaning they had exhausted many of their other treatment options. Carvykti last year generated $500 million in revenue. The therapy is one of a host of multiple myeloma treatments that have been approved in recent years, including Bristol Myers and 2seventy bio’s multiple myeloma cell therapy Abecma. In the pivotal study that led to its expanded approval to third-line patients, Abecma offered a survival benefit when results were adjusted for crossover, but showed no benefit when they were not adjusted. Carvykti sales eclipsed Abecma sales in the third quarter of 2023, and have remained higher since. But the pressing question for J&J and Legend remains whether they can keep up with demand for the cell therapy, which is not simple to make as each dose requires a patient’s own immune cells. Aside from its own manufacturing, J&J is partnered with Novartis to make commercial Carvykti. A J&J supply chain executive told Endpoints News in April that the company, alongside its partner Legend Biotech, hopes to double Carvykti production capacity by the end of 2024. #lucidquest #genetherapy #celltherapy

Kangstem Biotech's 14th shareholder's meeting held on the 21rd. Thanks to the support of shareholders, all of the company's agenda items were approved. After the meeting, followed by a Q&A session with shareholders on the progress and future schedule of clinical trials for the company's main pipeline, atopic dermatitis and osteoarthritis dermatitis. #kangstembiotech #stemcell #cell #stemcelltherapy #celltreatment #atopic #osteoarthritis

Sebia #FLC are the first EIA tests receiving 510(k) from the #FDA for the quantitative detection of both #kappa and #lambda free light chains in human serum specimens, intended for both aid of diagnosis and monitoring of Multiple #Myeloma and Immunoglobulin Light-Chain (AL-) amyloidosis.  Click to learn more. #sebiausa #Freelightchain #multiplemyeloma #alamaloidosis

The last ImmunoWatch for 2023 is focused on Therapeutic Cytokines, download it to learn more on this innovative field of biotherapies :) And if you look closely enough you'll find the topics for our 2024 Watches! #mabdesign #therapeuticcytokines #biotherapies #mabdesignwatchs

Social Pharma Patient-Centric Marketing socialpharma.net >>> Gene&Cell Therapy >> Merck's big ADC move; Latest from #ESMO23; How Eli Lilly is thinking about deals; AI-designed drugs face reckoning in clinic; and more #lucidquest #genetherapy #celltherapy

Another historical day, Avacincaptad Pegol (IZERVAY) FDA approved for geographic atrophy AMD. So proud of this drug that we envisioned it in 2008. I promoted and co-designed the phase I trial together with Samir Patel, former CEO of Ophthotech, nowadays Iveric Bio. The drug at that time was intended to be used in combination with anti-VEGF for exudative AMD, but we pushed to try it in geographic atrophy. From there, we performed a Phase I study in 2009, intravitreal anti-complement therapy first-in-human. The first patient ever done was in Barcelona. We injected only five times a year, it had never been done before, and safety was the priority. Some effect was seen in small lesions and a biological effect after the loading phase. I am so proud and happy of this seed many years ago when very few people cared about atrophic AMD, nowadays has been converted into a drug that has met the pre-specified endpoints in 2 Phase 3 clinical trials and is finally approved. Welcome to our baby Izervay! Below the old slides, look vintage already #amd #geographicatrophy #maculardegeneration #macula #retina #clinicalresearch #clinicaltrials #blindness #vision #innovation #ophthalmology #complement #atrophy #persistence #izervay Iveric Bio, An Astellas Company #pioneering #avacincaptad

💥💥New Publication Alert💥💥 I'm excited to share our newly published paper titled "Progress of Phage Therapy Research as an Alternative to Antibiotics: Current Status, Challenges, and The Future of Phage Therapeutics". I appreciate the big contributions of my co-authors: Samuel Awoniyi, Bisola Bolarinde, and Awotimiro Oluwafemi I also acknowledge the support of the Young Researchers' Hub - OAU, under the leadership of Taiwo Sokunbi. Here's the link to the full article: https://lnkd.in/eE8SVa83 #publichealth #AMR #phagetherapyawareness #bacteriophages